eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

2/2022
vol. 14
 
Share:
Share:
more
 
 
abstract:
Original paper

Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators

Mona Malekzadeh Moghani
1, 2
,
Zahra Siavashpour
1
,
Oleksander Ogorodniitchouk
2
,
Pablo Moreno-Acosta
3
,
Delphine Plattard
2
,
Alexis Vallard
2
,
Sandrine Sotton
2
,
Wafa Bouleftour
2
,
Julien Langrand-Escure
2
,
Nicolas Magné
2

1.
Department of Radiation-Oncology, Shohadaye Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Teheran, Iran
2.
Department of Radiotherapy, Lucien Neuwirth Cancer Institute, Saint-Etienne, France
3.
Research group in Cancer Biology, Research Branch, National Cancer Institute, Bogota, Colombia
J Contemp Brachytherapy 2022; 14, 2: 183–188
Online publish date: 2022/04/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
The present study aimed to assess the correlation between dose to pelvic lymph nodes and to point B with tandem-ring (TR) applicators for intra-cavitary brachytherapy treatment of locally advanced cervical cancer.

Material and methods
Cervical cancer patients treated at brachytherapy department of Lucien Neuwirth Cancer Center, from 2015 to 2018, were included. Target delineation was performed in compliance with GEC-ESTRO guidelines. Revised American Brachytherapy Society (ABS) point A was determined (ARN (right) and ALN (left)) as well as Manchester point B. Prescription dose was 25-35 Gy in 5 fractions. Pelvic lymph nodes were delineated, then dose to points A and B, and dose-volume histogram (DVH) parameters of delineated lymph nodes were extracted. Significant relationships or correlations between lymph nodes reference points, dosage to points B, and their DVH parameters were investigated.

Results
The mean dose and mean percentage of the prescription dose to the left and right points B were 4.6 ±0.18 Gy and 82.08 ±0.72%, respectively. Pearson correlation coefficient R = 0.81 (p-value = 0.00) between dose to ARN and ALN points and prescription dose was obtained. Negative correlation between CTVHR volume and difference between French and ABS prescription points was found.

Conclusions
Dose to point B can be a moderate surrogate for maximum, minimum, and median dose to the internal iliac and presacral lymph node, but cannot be for maximum dose to the obturator lymph node. Points B cannot be a reliable substitute for common and external iliac chains.

keywords:

brachytherapy, cervical cancer, pelvic lymph node, tandem-ring applicator, point B

 
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.